Role of MRP1 in multidrug resistance in acute myeloid leukemia

Leukemia

Volumn 13, Issue 4, 1999, Pages 578-584

  Legrand, O ^a   Zittoun, R ^b   Marie, J P ^b  

^a HÔTEL DIEU   (France)

^b NONE

Author keywords

Acute myeloid leukemia; Functional test; MDR; MRP1; Prognostic factor

Indexed keywords

ANTHRACYCLINE; ETACRYNIC ACID; ETOPOSIDE; GENISTEIN; INDOMETACIN; MULTIDRUG RESISTANCE PROTEIN; PROBENECID; PYRIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

EID: 0032935220     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401361     Document Type: Review

References (76)

1. Marie JP, Zhou DC, Gurbuxani S, Legrand O, Zittoun R. MDR1/P-glycoprotein in haematological neoplasms, Eur J Cancer 1996; 32A: 1034-1038.
2. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Ducan AMV, Deelay RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
3. Cole SPC, Deelay RG. Multidrug resistance-associated protein: sequence correction. Science 1993; 260: 879.
4. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia 1994; 8: 2163-2168.
5. te Boekhorst PA, Lowenberg B, van Kapel J, Nooter K, Sonneveld P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 1995; 9: 1025-1031.
6. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH, Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995; 85: 186-193.
7. Zhou DC, Zittoun R, Marie J-P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995; 9: 1661-1666.
8. Filipits M, Suchomel RW, Zöchbauer S, Brunner R, Lechner K, Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin Cancer Res 1997; 3: 1419-1425.
9. Lohri A, van Hille B, Bacchi M, Fopp M, Joncourt F, Reuter J, Cerny T, Fey MF, Herrman R. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss group for Clinical Cancer Research (SAKK), Eur J Haematol 1997; 59: 206-215.
10. Leith CP, Kopecky KJ, Chen IM, Slovak M, Head DR, Weick J, Appelbaum FR, Willman CL. Frequency and clinical significance of expression of the multidrug resistance proteins, MDR1, MRP and LRP in acute myeloid leukemia patients less than 65 years old. A Southwest Oncology Group study. Blood 1997; 90: 389a (Abstr.).
11. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie J-P. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91: 4480-4488.
12. Bakos E, Hegedus T, Hollo Z, Welker E, Tusnady GE, Zaman GJ, Flens MJ, Varadi A, Sarkadi B. Membrane topology and glycosylation of the human multidrug resistance-associated protein. J Biol Chem 1996; 271: 12322-12326.
13. Zaman GR, Flens MJ, van Leusden MR. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 1994; 91: 8822-8826.
14. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increase resistance to natural product drugs. Cancer Res 1994; 54: 357-361.
15. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-5910.
16. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJLM, Scheper RJ, Zaman GJR. Immunochemical detection of the multi-drug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994; 54: 4557-4563.
17. r 190 000 multidrug protein, MRP, with monoclonal antibodies. Cancer Res 1994; 54: 5788-5792.
18. 4 and structurally related conjugates. J Biol Chem 1994; 25: 27807-27810.
19. Gekeler V, Ise W, Sanders KH, Ulrich WR, Beck J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 1995; 208: 345-352.
20. Müller M, Meijer C, Zaman GJR, Borst P, Scheper RJ, Mulder NH, de Vries EG, Jansen PL. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 1994; 91: 13033-13037.
21. Versantvoort CH, Broxterman HJ, Bagrij T, Scheper RJ, Twentyman PR. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 1995; 72: 82-89.
22. Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RP, Baas F, Borst P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 1995; 92: 7690-7694.
23. Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cell compared with P-glycoprotein-expressing cancer cells. Mol Pharmacol 1998; 53: 141-147.
24. Lorico A, Rappa G, Flavell RA. Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res 1996; 56: 5351-5355.
25. Kuss BJ, Deeley RG, Cole SPC, Willman CL, Kopecky KJ, Wolman SR, Eyre HJ, Lane SA, Nancarrow JK, Whitmore SA, Callen DF. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet 1994; 343: 1531-1534.
26. Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, de Haas M, Smith AJ, Broxterman HJ, Mulder NH, de Vries EGE, Baas F, Borst P. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter in human multidrug resistant lung cancer cell lines. Cancer Res 1993; 53: 1747-1750.
27. Burger H, Nooter K, Sonneveld P, van Wingerden KE, Zaman GJR, Stoter G. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukemia. Br J Haematol 1994; 88: 348-356.
28. Burger H, Nooter K, Zaman GJR, Sonneveld P, van Wingerden KE, Oostrum RG, Stoter G. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 1994; 8: 990-997.
29. Ma L, Krishnamachary N, Center MS. Phosphorylation of multidrug resistance associated protein gene encoded protein P190. Biochemistry 1995; 34: 3338-3343.
30. Zhu Q, Center MS. Cloning and sequence analysis of promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin. Cancer Res 1994; 54: 4488-4492.
31. Zhu Q, Sun H, Center MS. Functional analysis of the nucleotide binding domains of the multidrug resistance protein (MRP). Oncol Res 1997; 9: 229-236.
32. Nooter K, Burger H, Stoter G. Multidrug resistance-associated protein (MRP) in haematological malignancies. Leuk Lymphoma 1996; 20: 381-387.
33. Slapak CA, Mizunuma N, Kufe DW. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 1994; 84: 3113-3121.
34. Zhou DC, Ramond S, Viguié F, Faussat AM, Zittoun R, Marie J-P. Progressive resistance to homoharringtonine in human myeloleukemia K562 cells: relationship to sequential emergence of MRP and MDR1 gene overexpression and MDR1 gene translation. Int J Cancer 1996; 65: 365-371.
35. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SPC, Sehested M. Sequential coexpression of the multidrug resistance gene MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 1995; 55: 459-462.
36. Slapak CA, Daniel JC, Levy SB. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression. Cancer Res 1990; 50: 7895-7901.
37. Richon VM, Weich N, Leng L, Kiyokawa H, Ngo L, Rifkind RA, Marks PA. Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation. Proc Natl Acad Sci USA 1991; 88: 1666-1670.
38. + acute myeloid leukemia cells. Blood 1993; 82: 3157-3162.
39. Legrand O, Perrot J-Y, Tang RP, Simonin G, Gurbuxani S, Zittoun R, Marie J-P. Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haematopoietic cells. Br J Haematol 1996; 94: 23-33.
40. + peripheral cells. Clin Cancer Res 1998; 4: 1727-1736.
41. Legrand O, Simonin G, Zittoun R, Marie J-P. Both P-gp and MRP contribute to drug resistance in AML. Leukemia 1998; 12: 1327-1328.
42. Ross DD, Doyle LA, Schiffer CA, Lee EJ, Grant CE, Cole SPC, Deeley RG, Yang W, Tong Y. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia patients. Leukemia 1996; 10: 48-58.
43. Schuurhuis GJ, Broxterman HJ, Ossenkeppele GJ, Baak JPA, Eekman CA, Kuiper CM, Feller N, van Heijningen THM, Klumper E, Pierters R, Lankelma J, Pinedo HM. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with beta-D-arabinosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1995; 1: 81-88.
44. Filipits M, Suchomel RW, Lechner K, Pirker R. Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source and disease status. Leukemia 1997; 11: 1073-1077.
45. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJT, Juijn JA, Baas F, Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997; 57: 3557-3547.
46. den Boer ML, Pieters R, Kazemier KM, Rottier MM, Zwaan CM, Kaspers GJ, Janka-Schaub G, Henze G, Creutzig U, Scheper RJ, Veerman AJ. Relationship between major vault protein/lung resistance protein multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092-2098.
47. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dielt M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Kumar Svrivastava D, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance in patient tumors: consensus recommendations. Cancer Res 1996; 56: 3010-3020.
48. Marie J-P, Huet S, Faussat A-M, Perrot J-Y, Chevillard S, Barbu V, Bayle C, Boutonnat J, Calvo F, Campos-Guyotat L, Colosetti P, Cazin J-L, De Cremoux P, Delvincourt C, Demur C, Drenou B, Fenneteau O, Feuillard J, Garnier-Suillerot A, Genne P, Gorisse M-C, Gosselin P, Jouault H, Lacave R, Le Calvez G, Léglise M-C, Léonce S, Manfait M, Maynadié M, Merle-Béral H, Merlin J-L, Mousseau M, Morjani H, Picard F, Pinguet F, Poncelet P, Racadot E, Raphael M, Richard B, Rossi J-F, Schlegel N, Vielh P, Zhou DC, Robert J. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of 'Assistance Publique-Hôpitaux de Paris'. Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 1997; 11: 1086-1094.
49. Marie J-P, Legrand O, Perrot J-Y, Chevillard S, Huet S, Robert J. Measuring multidrug resistance expression in human malignancies: elaboration of concensus recommendations. Semin Hematol 1997; 34: 63-71.
50. Bailly JD, Muller C, Jaffrézou JP, Demur C, Gassar G, Bordier C, Laurent G. Lack of correlation between expression and function of Pgp in acute myeloid leukemia cells. Leukemia 1995; 9: 799-807.
51. Davey MW, Hargrave RM, Davey RA. Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells. Leukemia Res 1996; 20: 657-664.
52. Webb M, Raphael CL, Asbahr H, Erber WN, Meyer BF. The detection of rhodamine 123 efflux at low levels of drug resistance. Br J Haematol 1996; 93: 650-655.
53. Twentyman PR, Rhodes T, Rayner S. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotype. Eur J Cancer 1994; 30A: 1360-1369.
54. Broxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Waher DC, Ossenkoppele GJ, Schuurhuis GJ. Theorical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia. Leukemia 1997; 11: 1110-1118.
55. Feller N, Kuiper CM, Lankelma J, Ruhdal JK, Scheper RJ, Pinedo HM, Broxterman HJ. Functional detection of MDR1/p170 and MRP/p190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 1995; 72: 543-550.
56. Pall G, Spitaler M, Hofmann J, Thaler J, Ludescher C. Multidrug resistance in acute leukemia: a comparison of different diagnostic method. Leukemia 1997; 11: 1067-1072.
57. Minderman H, Vanhoefer U, Toth K, Yin MB, Minderman MD, Wrzosek C, Slovak ML, Rustum YM. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry 1996; 25: 14-20.
58. Breeuwer P, Drocourt JL, Bunschoten N, Zwietering MH, Rombouts FM, Abee T. Characterization of uptake and hydrolysis of fluorocein diacetate and carboxyfluorocein diacetate by intracellular esterases in saccharomyces cerevisiae, which result in accumulation of fluorescent product. Appl Environ Microbiol 1995; 61: 1614-1619.
59. Hollo Z, Homolya L, Hegedus T, Sarkadi B. Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett 1996; 383: 99-105.
60. Draper MP, Martell RL, Levy SB. Active efflux of the free acid form of the fluorescent dye 2′, 7′-bis(2-carboxyethyl)-5(6)-carboxyfluorescein in multidrug-resistance-protein-overexpressing murine and human leukemia cells. Eur J Biochem 1997; 243: 219-224.
61. Essodaigui M, Broxterman HJ, Garnier-Suillerot A. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 1998; 37: 2243-2250.
62. Gollapudi S, Kim CH, Tran BN, Sangha S, Gupta S. Probenecid reverses multidrug resistance in resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chernother Pharmacol 1997; 40: 150-155.
63. Versantvoort CH, Bagrij T, Wright KA, Twentyman PR. On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the gluthatione status of cells overexpressing the multidrug resistance-associated protein (MRP). Int J Cancer 1995; 63: 855-862.
64. Vanhoefer U, Yin MB, Harstrick A, Seeber S, Rustum YM. Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N-nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Biochem Pharmacol 1997; 53: 801-809.
65. Chen ZS, Mutoh M, Sumizawa T, Furukawa T, Haraguchi M, Tani A, Akiyama S. Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells. Biochem Biophys Res Commun 1997; 236: 586-590.
66. Feller N, Broxterman HJ, Wahrer DC, Pinedo HM. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett 1995; 368: 385-389.
67. Vanhoefer U, Yin MB, Harstrick A, Seeber S, Rustum YM. Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N-nitrosourea associated with inhibition of multidrug resistance protein (MRP) function. Biochem Pharmacol 1997; 53: 801-809.
68. Zaman GJ, Cnubben NH, van Bladeren PJ, Evers R, Borst P. Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. FEBS Lett 1996; 391: 126-130.
69. Draper MP, Martell RL, Levy SB. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer 1997; 75: 810-815.
70. Chuman Y, Chen ZS, Seto K, Sumizawa T, Furukawa T, Tani A, Haraguchi M, Niwa K, Yamada K, Aikou T, Akiyama S. Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. Cancer Lett 1998; 129: 69-76.
71. Germann UA, Ford PJ, Shlyakhter D, Mason VS, Harding MW. Chemosensitization and drug accumulation effects of V-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 1997; 8: 141-155.
72. Naito S, Koike K, Ono M, Machida T, Tasaka S, Kiue A, Koga H, Kumazawa J. Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1 and MRP-mediated multidrug resistance. Oncol Res 1998; 10: 123-132.
73. Versantvoort CH, Rhodes T, Twentyman PR. Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer 1996; 74: 1949-1954.
74. Benderra Z, Morjani H, Trussardi A, Manfait M. Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistance MCF7 cells overexpressing the multidrug-resistance associated protein, Int J Oncol 1998; 12: 711-715.
75. +-ATPase-dependent activity of multidrug resistance-associated protein in homoharringtonine-resistant human leukemic K562 cells. Leukemia 1998; 12: 1539-1544.
76. Hornolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993; 268: 21493-21501.